Table 2.
Characteristics of three monoclonal antibodies against recombinant E2-AD protein of the vaccine C-strain
| Western blota (rE2-AD protein) | IFAb (virus infected cells) | Antibody binding/neutralization efficiencyc | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| mAb | Isotype | Epitope | C-strain | QZ-07 | HZ1-08 | C-strain | QZ-07 | HZ1-08 | C-strain | QZ-07 | HZ1-08 |
| 1E7 | IgG1 | Conformational epitope In antigenic unit B/C | - | - | - | + | + | + | 5.3/3.35 | 3.2/<1.7 | 2.9/<1.7 |
| 2B6 | IgG2b | Linear epitope at position 1-110 aa | + | ± | ± | + | - | - | 4.4/<1.7 | 0/0 | 0/0 |
| 6B8 | IgG2b | Conformational epitope in antigenic unit B/C | - | - | - | + | + | + | 5.6/4.85 | 4.4/<1.7 | 4.1/<1.7 |
aValues represent binding of mAbs to denatured prokaryotic-derived rE2 proteins as detected by Western blotting: "+"= strong reactivity; "±"= weak reactivity; "-"= no reactivity detected.
bValues represent binding of mAbs to native viral E2 proteins detected by immunofluorescence assay: "+"= fluorescent signal detected; "-"= no signal detected.
cIFA and neutralization assay were performed by serial dilutions of mAbs to assess the antibody binding and neutralization efficiency with different CSFV strains.